Logo image of ADMA

ADMA BIOLOGICS INC (ADMA) Stock Fundamental Analysis

NASDAQ:ADMA - Nasdaq - US0008991046 - Common Stock - Currency: USD

15.83  -0.56 (-3.42%)

After market: 15.84 +0.01 (+0.06%)

Fundamental Rating

6

ADMA gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. ADMA has an excellent financial health rating, but there are some minor concerns on its profitability. ADMA is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings would make ADMA suitable for growth investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

ADMA had positive earnings in the past year.
In the past year ADMA had a positive cash flow from operations.
In the past 5 years ADMA always reported negative net income.
ADMA had negative operating cash flow in 4 of the past 5 years.
ADMA Yearly Net Income VS EBIT VS OCF VS FCFADMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M

1.2 Ratios

With an excellent Return On Assets value of 17.44%, ADMA belongs to the best of the industry, outperforming 97.86% of the companies in the same industry.
Looking at the Return On Equity, with a value of 29.38%, ADMA belongs to the top of the industry, outperforming 98.21% of the companies in the same industry.
ADMA has a better Return On Invested Capital (26.25%) than 99.29% of its industry peers.
Industry RankSector Rank
ROA 17.44%
ROE 29.38%
ROIC 26.25%
ROA(3y)-17.8%
ROA(5y)-25.57%
ROE(3y)-38.32%
ROE(5y)-77.03%
ROIC(3y)N/A
ROIC(5y)N/A
ADMA Yearly ROA, ROE, ROICADMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K -2K

1.3 Margins

ADMA has a better Profit Margin (17.80%) than 96.61% of its industry peers.
Looking at the Operating Margin, with a value of 30.01%, ADMA belongs to the top of the industry, outperforming 98.39% of the companies in the same industry.
Looking at the Gross Margin, with a value of 48.93%, ADMA is in the better half of the industry, outperforming 77.32% of the companies in the same industry.
Industry RankSector Rank
OM 30.01%
PM (TTM) 17.8%
GM 48.93%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADMA Yearly Profit, Operating, Gross MarginsADMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

8

2. Health

2.1 Basic Checks

ADMA has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for ADMA has been increased compared to 1 year ago.
ADMA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ADMA has been reduced compared to a year ago.
ADMA Yearly Shares OutstandingADMA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M
ADMA Yearly Total Debt VS Total AssetsADMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

An Altman-Z score of 15.93 indicates that ADMA is not in any danger for bankruptcy at the moment.
ADMA has a Altman-Z score of 15.93. This is amongst the best in the industry. ADMA outperforms 91.79% of its industry peers.
ADMA has a debt to FCF ratio of 1.29. This is a very positive value and a sign of high solvency as it would only need 1.29 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 1.29, ADMA belongs to the top of the industry, outperforming 95.18% of the companies in the same industry.
A Debt/Equity ratio of 0.44 indicates that ADMA is not too dependend on debt financing.
ADMA has a Debt to Equity ratio of 0.44. This is in the lower half of the industry: ADMA underperforms 74.46% of its industry peers.
Although ADMA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 1.29
Altman-Z 15.93
ROIC/WACC2.76
WACC9.5%
ADMA Yearly LT Debt VS Equity VS FCFADMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M 150M

2.3 Liquidity

ADMA has a Current Ratio of 7.09. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ADMA (7.09) is better than 68.04% of its industry peers.
ADMA has a Quick Ratio of 3.26. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.26, ADMA is doing worse than 60.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.09
Quick Ratio 3.26
ADMA Yearly Current Assets VS Current LiabilitesADMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

8

3. Growth

3.1 Past

ADMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 354.55%, which is quite impressive.
ADMA shows a strong growth in Revenue. In the last year, the Revenue has grown by 63.40%.
Measured over the past years, ADMA shows a very strong growth in Revenue. The Revenue has been growing by 72.31% on average per year.
EPS 1Y (TTM)354.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1400%
Revenue 1Y (TTM)63.4%
Revenue growth 3Y82.9%
Revenue growth 5Y72.31%
Sales Q2Q%78.13%

3.2 Future

Based on estimates for the next years, ADMA will show a very strong growth in Earnings Per Share. The EPS will grow by 68.48% on average per year.
The Revenue is expected to grow by 29.20% on average over the next years. This is a very strong growth
EPS Next Y504.08%
EPS Next 2Y172.64%
EPS Next 3Y109.98%
EPS Next 5Y68.48%
Revenue Next Year64.76%
Revenue Next 2Y36.9%
Revenue Next 3Y32.44%
Revenue Next 5Y29.2%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ADMA Yearly Revenue VS EstimatesADMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
ADMA Yearly EPS VS EstimatesADMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

ADMA is valuated quite expensively with a Price/Earnings ratio of 56.54.
Based on the Price/Earnings ratio, ADMA is valued cheaper than 93.39% of the companies in the same industry.
ADMA's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 29.75.
The Price/Forward Earnings ratio is 22.41, which indicates a rather expensive current valuation of ADMA.
Based on the Price/Forward Earnings ratio, ADMA is valued cheaply inside the industry as 93.57% of the companies are valued more expensively.
ADMA's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.44.
Industry RankSector Rank
PE 56.54
Fwd PE 22.41
ADMA Price Earnings VS Forward Price EarningsADMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ADMA is valued cheaply inside the industry as 94.82% of the companies are valued more expensively.
93.57% of the companies in the same industry are more expensive than ADMA, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 47.48
EV/EBITDA 31.59
ADMA Per share dataADMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ADMA's earnings are expected to grow with 109.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.11
PEG (5Y)N/A
EPS Next 2Y172.64%
EPS Next 3Y109.98%

More info and screens

0

5. Dividend

5.1 Amount

ADMA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADMA BIOLOGICS INC

NASDAQ:ADMA (3/3/2025, 8:10:52 PM)

After market: 15.84 +0.01 (+0.06%)

15.83

-0.56 (-3.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-03 2025-03-03/amc
Inst Owners88.05%
Inst Owner Change-1.68%
Ins Owners2.17%
Ins Owner Change2.74%
Market Cap3.74B
Analysts84
Price Target24.76 (56.41%)
Short Float %5.8%
Short Ratio5.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.22%
Min EPS beat(2)13.12%
Max EPS beat(2)59.31%
EPS beat(4)3
Avg EPS beat(4)-74.67%
Min EPS beat(4)-413.72%
Max EPS beat(4)59.31%
EPS beat(8)6
Avg EPS beat(8)-6.12%
EPS beat(12)8
Avg EPS beat(12)-3.82%
EPS beat(16)11
Avg EPS beat(16)-2.62%
Revenue beat(2)2
Avg Revenue beat(2)16.3%
Min Revenue beat(2)10.99%
Max Revenue beat(2)21.61%
Revenue beat(4)4
Avg Revenue beat(4)9.23%
Min Revenue beat(4)0.42%
Max Revenue beat(4)21.61%
Revenue beat(8)8
Avg Revenue beat(8)7.55%
Revenue beat(12)12
Avg Revenue beat(12)8.5%
Revenue beat(16)16
Avg Revenue beat(16)8.17%
PT rev (1m)0%
PT rev (3m)3.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.23%
EPS NY rev (1m)0%
EPS NY rev (3m)0.49%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.04%
Valuation
Industry RankSector Rank
PE 56.54
Fwd PE 22.41
P/S 9.78
P/FCF 47.48
P/OCF 43.48
P/B 16.14
P/tB 16.42
EV/EBITDA 31.59
EPS(TTM)0.28
EY1.77%
EPS(NY)0.71
Fwd EY4.46%
FCF(TTM)0.33
FCFY2.11%
OCF(TTM)0.36
OCFY2.3%
SpS1.62
BVpS0.98
TBVpS0.96
PEG (NY)0.11
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 17.44%
ROE 29.38%
ROCE 33.23%
ROIC 26.25%
ROICexc 35.04%
ROICexgc 35.59%
OM 30.01%
PM (TTM) 17.8%
GM 48.93%
FCFM 20.59%
ROA(3y)-17.8%
ROA(5y)-25.57%
ROE(3y)-38.32%
ROE(5y)-77.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.98
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 1.29
Debt/EBITDA 0.82
Cap/Depr 88.1%
Cap/Sales 1.89%
Interest Coverage 9.93
Cash Conversion 69.9%
Profit Quality 115.69%
Current Ratio 7.09
Quick Ratio 3.26
Altman-Z 15.93
F-Score8
WACC9.5%
ROIC/WACC2.76
Cap/Depr(3y)167.02%
Cap/Depr(5y)188.21%
Cap/Sales(3y)9.22%
Cap/Sales(5y)14.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)354.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1400%
EPS Next Y504.08%
EPS Next 2Y172.64%
EPS Next 3Y109.98%
EPS Next 5Y68.48%
Revenue 1Y (TTM)63.4%
Revenue growth 3Y82.9%
Revenue growth 5Y72.31%
Sales Q2Q%78.13%
Revenue Next Year64.76%
Revenue Next 2Y36.9%
Revenue Next 3Y32.44%
Revenue Next 5Y29.2%
EBIT growth 1Y8410.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year735.64%
EBIT Next 3Y140.66%
EBIT Next 5Y89%
FCF growth 1Y179.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y200.53%
OCF growth 3YN/A
OCF growth 5YN/A